Stéphane Bancel, Moderna CEO (Joel Saget/AFP via Getty Images)
January 9, 2023 04:55 PM ESTUpdated January 10, 10:24 AM
Pharma
Coronavirus

Up­dat­ed: Mod­er­na rounds out 2022 with $18.4B in vac­cine sales, boosts R&D bud­get for 2023

Nicole DeFeudis

Editor

Mod­er­na CEO Stéphane Ban­cel is revving the en­gines go­ing in­to 2023, with a whop­ping $4.5 bil­lion R&D bud­get and a new pri­or­i­ty re­view vouch­er. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

Trodelvy and Keytru­da com­bo suc­ceeds in Phase 3 breast can­cer study

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

FDA plans to ban phar­ma em­ploy­ees from serv­ing on ad­comms. The im­pact will be lim­it­ed

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times